DSM-Firmenich Valuation Multiples

Discover DSM-Firmenich's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Qinghai Salt Lake Industry, Ningxia Baofeng Energy Group, Borouge, OMV and more.

DSM-Firmenich Overview

About DSM-Firmenich

DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.


Founded

2022

HQ

Switzerland

Employees

27.0K

Sectors

Financials (LTM)

Revenue: $13B
EBITDA: $2B

EV

$27B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DSM-Firmenich Financials

DSM-Firmenich reported last 12-month revenue of $13B and EBITDA of $2B.

In the same LTM period, DSM-Firmenich generated $6B in gross profit, $2B in EBITDA, and $714M in net income.

Revenue (LTM)


DSM-Firmenich P&L

In the most recent fiscal year, DSM-Firmenich reported revenue of $15B and EBITDA of $4B.

DSM-Firmenich is profitable as of last fiscal year, with gross margin of 27%, EBITDA margin of 30%, and net margin of 6%.

See analyst estimates for DSM-Firmenich
LTMLast FY202320242025202620272028
Revenue$13B$15B$12B$15B$10B
Gross Profit$6B$4B$3B$5B$4B
Gross Margin49%27%25%33%39%
EBITDA$2B$4B$946M$2B$4B
EBITDA Margin19%30%8%14%43%
EBIT Margin10%11%(5%)4%7%
Net Profit$714M$825M$2B$286M($1B)
Net Margin6%6%20%2%(12%)
Net Debt-$3B---

Financial data powered by Morningstar, Inc.

DSM-Firmenich Stock Performance

DSM-Firmenich has current market cap of $23B, and enterprise value of $27B.

Market Cap Evolution


DSM-Firmenich's stock price is $94.71.

DSM-Firmenich share price increased by 0.3% in the last 30 days, and decreased by 2.9% in the last year.

DSM-Firmenich has an EPS (earnings per share) of $3.33.

See more trading valuation data for DSM-Firmenich
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$27B$23B4.1%0.3%27.5%-2.9%$3.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DSM-Firmenich Valuation Multiples

DSM-Firmenich trades at 2.2x EV/Revenue multiple, and 11.6x EV/EBITDA.

See NTM and 2027E valuation multiples for DSM-Firmenich

EV / Revenue (LTM)


DSM-Firmenich Financial Valuation Multiples

As of July 2, 2026, DSM-Firmenich has market cap of $23B and EV of $27B.

DSM-Firmenich has a P/E ratio of 32.8x.

LTMLast FY202320242025202620272028
EV/Revenue2.2x1.8x2.2x1.9x2.6x
EV/EBITDA11.6x6.2x28.9x13.4x6.2x
EV/EBIT21.7x17.4x(47.1x)44.3x37.8x
EV/Gross Profit4.4x6.8x9.2x5.6x6.8x
P/E32.8x28.4x9.6x82.1x(19.0x)
EV/FCF31.7x36.3x42.8x23.8x36.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DSM-Firmenich Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DSM-Firmenich Margins & Growth Rates

DSM-Firmenich decreased revenue by 30% and EBITDA by 54% in the last fiscal year.

In the most recent fiscal year, DSM-Firmenich reported gross margin of 27%, EBITDA margin of 30%, and net margin of 6%.

See estimated margins and future growth rates for DSM-Firmenich

DSM-Firmenich Margins

Last FY202420252026202720282029
Gross Margin27%33%39%39%
EBITDA Margin30%14%43%19%
EBIT Margin11%4%7%9%
Net Margin6%2%(12%)6%
FCF Margin5%8%7%9%

DSM-Firmenich Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(30%)20%(29%)2%
Gross Profit Growth3%63%(17%)3%
EBITDA Growth(54%)116%115%(54%)
EBIT Growth(40%)(206%)17%31%
Net Profit Growth(27%)(88%)(532%)(149%)
FCF Growth29%80%(35%)31%

Data powered by FactSet, Inc. and Morningstar, Inc.

DSM-Firmenich Operational KPIs

DSM-Firmenich's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.

DSM-Firmenich's Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DSM-Firmenich's Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for DSM-Firmenich
LTMLast FY202320242025202620272028
Rule of 403%21%---
Bessemer Rule of X(20%)23%---
Revenue per Employee-$0.6M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-10%14%14%14%
G&A Expenses to Revenue-7%10%8%10%
R&D Expenses to Revenue5%5%6%7%8%
Opex to Revenue-22%29%29%32%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

DSM-Firmenich Competitors

DSM-Firmenich competitors include Qinghai Salt Lake Industry, Ningxia Baofeng Energy Group, Borouge, OMV, International Flavors & Fragrances, Ems-Chemie, PPG, Dow, Hengli Petrochemical and DuPont.

Most DSM-Firmenich public comparables operate across Chemicals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Qinghai Salt Lake Industry8.6x6.2x16.2x11.0x
Ningxia Baofeng Energy Group3.6x3.3x10.0x8.6x
Borouge4.0x3.9x10.6x10.6x
OMV0.8x0.8x3.2x2.9x
International Flavors & Fragrances2.4x2.4x12.5x12.4x
Ems-Chemie7.7x7.9x24.2x24.4x
PPG2.1x2.0x11.8x11.8x
Dow0.9x0.8x10.9x7.1x

This data is available for Pro users. Sign up to see all DSM-Firmenich competitors and their valuation data.

Start Free Trial

Acquisitions by DSM-Firmenich

DSM-Firmenich has acquired 2 companies to date.

Last acquisition by DSM-Firmenich was on April 19th 2023. DSM-Firmenich acquired Adare Biome for $297M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by DSM-Firmenich

Adare Biome
DSM
Description
Adare Biome is a biotechnology firm based in Barcelona, Spain, specializing in microbiome-based postbiotics for human and animal health applications. The company develops targeted microbial solutions to modulate gut health, immune responses, and metabolic functions using proprietary strains isolated from natural sources. Adare Biome partners with pharmaceutical and nutraceutical companies to deliver clinical-stage products addressing conditions like inflammatory bowel disease and obesity. Founded in 2019 as a spin-off from Adare Pharmaceuticals, it leverages advanced fermentation and encapsulation technologies for stable, scalable postbiotic formulations.
DSM is a Dutch multinational specializing in nutrition, health, and sustainable materials, generating €12 billion in annual sales post its 2023 merger with Firmenich to form dsm-firmenich. Headquartered in Kaiseraugst, Switzerland, it employs 30,000 people across 60 countries, supplying omega-3s for food fortification, enzymes for animal feed, and engineering plastics for automotive components like airbag housings.
HQ CountryFranceNetherlands
HQ City
Paris
Heerlen
Deal Date19 Apr 20233 Apr 2023
Valuation$297Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DSM-Firmenich acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by DSM-Firmenich

DSM-Firmenich has invested in 1 company to date.

Latest investment by DSM-Firmenich was on March 13th 2024. DSM-Firmenich invested in Cynomys in their $2M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by DSM-Firmenich

Cynomys
Description
Cynomys is an Italian IoT company that patented sensors for monitoring over 30 parameters in livestock farms including welfare, emissions, and resource use. Launched in 2018 from Modena, the cloud-connected devices track temperature, humidity, feed intake, and ammonia levels for cattle, swine, and poultry operations. Cynomys serves feed producers and large farms in Italy, Spain, France, Netherlands, and Mexico, optimizing productivity and sustainability via remote dashboards.
HQ CountryItaly
HQ City
Ronco Scrivia
Deal Date13 Mar 2024
RoundSeed
Raised$2M
InvestorsFarming Future; PLUS9; DSM-Firmenich; SVG Ventures; Levante Capital
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DSM-Firmenich investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DSM-Firmenich

Who are competitors of DSM-Firmenich?DSM-Firmenich main competitors include Qinghai Salt Lake Industry, Ningxia Baofeng Energy Group, Borouge, OMV, International Flavors & Fragrances, Ems-Chemie, PPG, Dow, Hengli Petrochemical, DuPont.

See public comps similar to DSM-Firmenich

Lists including DSM-Firmenich

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial